RxDoctor Payments Data

Manjunath Benakanahalli, MD

Internal Medicine · Brandon, FLNPI 1619067428

Payments from drug & device makers

$879in general payments, 2019–2025

Across 13 payments — averaging $67.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$356
  • Amgen$131
  • Sanofi-aventis U.S. LLC$125
  • Abbott$104
  • Boehringer Ingelheim$91
  • Bayer$24
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$879100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$879 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$641,479
Medicare patients
396
Services billed
8,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$156,840
OzempicSemaglutide106$153,302
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$38,399
RybelsusSemaglutide19$37,649
JardianceEmpagliflozin31$25,789
MyrbetriqMirabegron37$25,762
MounjaroTirzepatide11$24,420
JanuviaSitagliptin Phosphate28$15,893
TradjentaLinagliptin21$13,162
EntrestoSacubitril/Valsartan12$11,647
Breo ElliptaFluticasone/Vilanterol13$8,284
Telmisartan205$5,689
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$4,147
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,089
Fosfomycin Tromethamine12$2,952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$356$190,952125 claims
PfizerEliquis$19$156,840166 claims
Boehringer IngelheimJardiance, Tradjenta$91$38,95152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →